- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Metastatic castration-resistant prostate cancer (mCRPC)
- Meeting Date: November 2023
- Public Summary Document (PSD) November 2023 PBAC Meetings - (PDF 1.4MB)
- Public Summary Document (PSD) November 2023 PBAC Meetings - (Word 981KB)
Olaparib – November 2023
Olaparib (prostate cancer): Tablet 100 mg, Tablet 150 mg; Lynparza®
Last updated
15 March 2024